A phase 1 dose-escalation, single center trial of intratumorally delivered pan-ErbB CAR-T in HNSCC (NCT01818323) [134] was reported at AACR in 2017 [135] and at ASCO in 2018 [136], using T1E28ζ, a CAR containing a promiscuous ErbB ligand (which engages 8/9 ErbB homo/heterodimers) coupled to a CD28 + CD3ζ endodomain and 4αβ, an IL-4-responsive chimeric cytokine receptor which enables IL-4-driven selective CAR T-cell enrichment/expansion during manufacture [137]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.